Analyst Price Targets — DXCM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 1, 2026 1:12 pm | — | Bernstein | $77.00 | $61.03 | TheFly | DexCom price target lowered to $77 from $83 at Bernstein |
| May 1, 2026 12:47 pm | — | Robert W. Baird | $80.00 | $61.83 | TheFly | DexCom price target lowered to $80 from $87 at Baird |
| May 1, 2026 12:26 pm | Anthony Petrone | Mizuho Securities | $75.00 | $61.65 | TheFly | DexCom price target lowered to $75 from $90 at Mizuho |
| May 1, 2026 11:53 am | — | Raymond James | $81.00 | $59.55 | TheFly | DexCom price target lowered to $81 from $83 at Raymond James |
| May 1, 2026 10:39 am | — | Canaccord Genuity | $100.00 | $59.55 | TheFly | DexCom price target raised to $100 from $95 at Canaccord |
| May 1, 2026 9:24 am | — | Barclays | $67.00 | $59.55 | TheFly | DexCom price target lowered to $67 from $72 at Barclays |
| February 13, 2026 2:17 pm | — | Robert W. Baird | $87.00 | $70.67 | TheFly | DexCom price target raised to $87 from $82 at Baird |
| February 13, 2026 12:40 pm | Anthony Petrone | Mizuho Securities | $90.00 | $65.08 | TheFly | DexCom price target raised to $90 from $78 at Mizuho |
| February 13, 2026 11:56 am | — | Canaccord Genuity | $95.00 | $65.08 | TheFly | DexCom price target lowered to $95 from $99 at Canaccord |
| February 13, 2026 11:14 am | — | Barclays | $72.00 | $65.08 | TheFly | DexCom price target raised to $72 from $71 at Barclays |
Latest News for DXCM
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
While GLP-1 agonists have grabbed investor attention for their potential as weight loss aids, these medicines also form a crucial component of a broader set of tools to address type 2 diabetes. With about 40 million people in the United States suffering from diabetes, and incidents of type 2 diabetes rising across multiple demographics, this core function of this class of medicines is still just as relevant as it…
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on Thursday, May 14, 2026 from 1:15 PM until approximately 3:30 PM PDT (4:15 PM – 6:30 PM EDT). The event will include presentations from Dexcom management highlighting the company's market opportunities, business strategy, innovation efforts, and long-term financial outlook. Links to a live webcast of the event…
DXCM stock jumps on Q1 beat as revenues rise 15% and margins expand, with strong CGM demand and raised profitability outlook boosting momentum.
Revenue: $1.19 billion, up 15% from Q1 2025.US Revenue: $832 million, up 11% from Q1 2025.International Revenue: $360 million, up 26% from Q1 2025.Gross Profit
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.